Stryker Corp

SYK remains in a Stage 4 decline with price trading below all major moving averages on heavy selling volume. Despite extreme oversold readings, there is no clear exhaustion or reversal pattern visible. The medium-term bias is bearish and short-term conditions favour immediate participation on the downside (Sell Now). Deferring action risks deeper breakdowns, so selling into any minor relief rally is recommended.

• ↑Q2 revenue of $6.59B with 9.4% organic sales growth
• ↑Mako system surpasses 2M procedures, leading orthopedic robotics adoption
• ↓Production hindered by cyberattack, causing ongoing medical division backlogs